NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Indigo Acquisition Corp. (the "Company") announced today that it has consummated the sale of the full 1,500,000 units subject to the over-allotment option granted to the underwriters in connection with its initial public offering. The additional units were sold at $10.00 per unit, generating additional gross proceeds to the Company of $15,000,000 FORWARD-LOOKING STATEMENTS This press release contains statements that constitute "forward-looking statements." No assu ...

A registration statement on Form F-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission (the "SEC") (File Number: 333- 285856), as amended, and was declared effective by the SEC on May 30, 2025. The Offering was made by means of a prospectus, forming a part of the registration statement. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies of the prospectus relating to the Offering may be obtained, when available, f ...

A registration statement on Form F-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission (the "SEC") (File Number: 333- 285856), as amended, and was declared effective by the SEC on May 30, 2025. The Offering was made by means of a prospectus, forming a part of the registration statement. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies of the prospectus relating to the Offering may be obtained, when available, f ...

MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. ("Milestone") (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the "Offering") of (i) 31,500,000 of its common shares (the "Shares"), accompanying Series A common warrants (the "Series A Common Warrants") to purchase an aggregate of 31,500,000 com ...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to announce that it has today lodged a prospectus (“Prospectus”) with the Australian Securities and Investments Commission (“ASIC”) for an initial public offering to raise proceeds of A$75.0 million (before associated costs) (“Offer”). The Prospectus will assist the Compan ...

Core Viewpoint - Civista Bancshares, Inc. has announced a public offering of 3,294,120 common shares priced at $21.25 per share, aiming for an aggregate amount of $70.0 million, with an option for underwriters to purchase an additional 494,118 shares [1][2]. Group 1: Offering Details - The gross proceeds from the offering are expected to be approximately $70.0 million before discounts and expenses, potentially increasing to $80.5 million if the underwriters fully exercise their option [2]. - The offering is anticipated to close on July 14, 2025, subject to customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, which may include supporting organic growth opportunities and future strategic transactions [2]. Group 3: Management and Registration - Piper Sandler & Co. is the sole book-running manager for the offering, with several firms serving as co-managers [3]. - Civista has filed a shelf registration statement with the SEC, including a preliminary prospectus supplement for the offering [4]. Group 4: Company Overview - Civista Bancshares, Inc. is a financial services holding company with assets of $4.1 billion, headquartered in Sandusky, Ohio, and operates 42 locations across Ohio, Southeastern Indiana, and Northern Kentucky [6].

Core Points - Delixy Holdings Limited successfully closed its initial public offering (IPO) of 2,000,000 ordinary shares at a public offering price of US$4.00 per share, raising total gross proceeds of US$8 million [1][3] - The ordinary shares began trading on the Nasdaq Capital Market under the ticker symbol "DLXY" on July 9, 2025 [2] - Proceeds from the offering will be utilized for expanding product offerings, strengthening market position, potential strategic acquisitions, and general working capital [4] Company Overview - Delixy Holdings Limited is a Singapore-based company engaged in trading oil-related products, including crude oil and various oil-based products such as fuel oils, motor gasoline, and petrochemicals [8] - The company operates across Southeast Asia, East Asia, and the Middle East, establishing a strong presence in the region's oil trading markets [8] - Delixy leverages strong relationships with customers and suppliers, providing value-added services and financing capabilities to enhance its trading operations [8]

Core Viewpoint - Soleno Therapeutics, Inc. has announced a public offering of 2,352,941 shares of common stock priced at $85.00 per share, aiming to raise approximately $200 million before expenses [1][3]. Group 1: Offering Details - The public offering consists of 2,352,941 shares, with an additional 30-day option for underwriters to purchase up to 352,941 more shares at the same price [1]. - The offering is expected to close on or about July 11, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds will primarily fund the commercialization of VYKAT XR, the first approved therapy for hyperphagia in Prader-Willi syndrome, which received FDA approval on March 26, 2025 [3]. - Additional proceeds will support regulatory and market development activities in the EU, further R&D efforts, and general corporate purposes, including working capital and potential acquisitions [3]. Group 3: Underwriters - Goldman Sachs & Co. LLC, Guggenheim Securities, TD Cowen, Cantor, and Oppenheimer & Co. are serving as joint book-running managers for the offering [2]. Group 4: Company Overview - Soleno Therapeutics focuses on developing novel therapeutics for rare diseases, with VYKAT XR being its first commercial product aimed at treating hyperphagia in individuals aged 4 and older with Prader-Willi syndrome [6].

Core Viewpoint - Soleno Therapeutics, Inc. plans to offer and sell $200 million of its common stock in an underwritten public offering, with an additional option for underwriters to purchase up to $30 million more [1][2]. Group 1: Offering Details - The public offering is subject to market conditions, and there is no assurance regarding the completion or terms of the offering [1]. - Goldman Sachs & Co. LLC and Guggenheim Securities are acting as the joint book-running managers for the offering [2]. - The shares will be offered under a registration statement previously filed with the SEC, and a preliminary prospectus will be made available [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the commercialization of VYKAT™ XR, the first approved therapy for hyperphagia in Prader-Willi syndrome, which received FDA approval on March 26, 2025 [3]. - Proceeds will also support regulatory and market development activities in the EU, further R&D efforts, and general corporate purposes, including working capital and potential acquisitions [3][6].

Core Viewpoint - Masonglory Limited successfully closed its initial public offering, raising a total of $6,000,000 by offering 1,500,000 ordinary shares at a price of $4.00 per share, with trading commencing on Nasdaq under the ticker symbol "MSGY" [1][4]. Group 1: Offering Details - The offering closed on July 9, 2025, and the shares began trading on July 8, 2025 [1]. - The underwriter has an option to purchase an additional 225,000 ordinary shares within 45 days from the closing date to cover any over-allotments [2]. - The offering was conducted on a firm commitment basis, with D. Boral Capital LLC serving as the sole underwriter [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated as follows: approximately 15% for expanding the workforce, 15% for acquiring additional machinery, 15% for diversifying the project portfolio, 15% for strengthening marketing efforts, and 40% for working capital and other general corporate purposes [3]. Group 3: Company Background - Masonglory Limited, founded in 2018 in Hong Kong, specializes in providing wet trades and ancillary services to property developers and the Hong Kong government [7]. - The company is a registered specialist trade contractor since 2020, offering services that include plastering, tile laying, brick laying, floor screeding, and marble works [7].